专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2016141126A1 METHOD OF MAKING LIGNOCELLULOSIC COMPOSITES 审中-公开
标题翻译：制备液体复合材料的方法
公开(公告)号：WO2016141126A1
公开(公告)日：2016-09-09
申请号：PCT/US2016/020579
申请日：2016-03-03
申请人： SOLENIS TECHNOLOGIES, L.P.
发明人： VARNELL, Daniel, F.
IPC分类号： C09J189/00 , B27N3/00
CPC分类号： C08L97/02 , B27N1/02 , B27N3/002 , B27N3/02 , B27N3/04 , C09J189/00 , C12N9/80 , C12Y305/01005
摘要： A method of preparing a lignocellulosic composite comprising combining one or more lignocellulosic materials with a liquid curative, followed by the addition of one or more dry protein sources, forming the composition into a composite structure and then curing the composite structure.
摘要翻译：一种制备木质纤维素复合材料的方法，包括将一种或多种木质纤维素材料与液体固化剂混合，然后加入一种或多种干燥蛋白质源，将组合物形成复合结构，然后固化复合结构。

2. 发明申请

WO2012031530A1 一种多靶点融合蛋白，其编码基因及应用审中-公开
公开(公告)号：WO2012031530A1
公开(公告)日：2012-03-15
申请号：PCT/CN2011/079042
申请日：2011-08-29
申请人：四川万可泰生物技术有限责任公司 , 王保宁
发明人：王保宁
IPC分类号： C07K14/20 , C12N15/31 , C12N15/63 , A61K39/02 , A61P1/04
CPC分类号： C07K14/205 , A61K39/02 , A61K39/105 , C07K14/245 , C07K2319/00 , C12N9/80 , C12Y305/01005

3. 发明申请

WO2010148459A1 SYNTHETIC OPERON 审中-公开
标题翻译：合成操作
公开(公告)号：WO2010148459A1
公开(公告)日：2010-12-29
申请号：PCT/AU2010/000806
申请日：2010-06-25
申请人： ONDEK PTY LTD , BENGHEZAL, Mohammed , DIEYE, Yakhya , SCHWANN, Carola , SEHNAL, Miriam , FULURIJA, Alma , MARSHALL, Barry
发明人： BENGHEZAL, Mohammed , DIEYE, Yakhya , SCHWANN, Carola , SEHNAL, Miriam , FULURIJA, Alma , MARSHALL, Barry
IPC分类号： C12N15/09 , C12N15/62 , A61P37/02 , C12N15/74
CPC分类号： C12N15/68 , C12N9/80 , C12N15/52 , C12N15/74 , C12Y305/01005
摘要： The present invention relates to synthetic operons. In particular, the present invention relates to a synthetic operon for integration into a bacterial chromosome of a bacterium comprising a promoter operably-linked to at least two genes, wherein at least one gene is a gene of interest and at least one gene is a gene essential to said bacterium.
摘要翻译：本发明涉及合成操纵子。特别地，本发明涉及用于整合到细菌细菌染色体中的合成操纵子，其包含与至少两个基因可操作地连接的启动子，其中至少一个基因是目的基因，并且至少一个基因是基因对所述细菌至关重要。

4. 发明申请

WO2005056040A2 SYSTEMS AND METHODS RELATED TO DEGRADATION OF UREMIC TOXINS 审中-公开
标题翻译：与尿毒素降解有关的系统和方法
公开(公告)号：WO2005056040A2
公开(公告)日：2005-06-23
申请号：PCT/US2004/040580
申请日：2004-12-03
申请人： BROWN UNIVERSITY , O'LOUGHLIN, Jill, A. , BRUDER, Jan, Markus , LYSAGHT, Michael, J.
发明人： O'LOUGHLIN, Jill, A. , BRUDER, Jan, Markus , LYSAGHT, Michael, J.
IPC分类号： A61K38/00
CPC分类号： C12Y305/01005 , A61K9/4866 , A61K9/4891 , A61K38/44 , A61K38/50 , A61K38/53 , C12Y107/03003 , C12Y305/0201 , C12Y603/01002 , Y02A50/473 , A61K2300/00
摘要： The present invention generally relates to the treatment of uremic toxins in vivo using uremic toxin-treating enzymes, and/or cells capable of producing uremic toxin-treating enzymes or otherwise reacting with uremic toxins. Non-limiting examples of cases where the treatment of uremic toxins is desired include renal disease or dysfunction, gout, subjects receiving chemotherapy, or the like. In one aspect, the treatment includes an oral delivery composition able to reduce the blood concentration of one or more non-protein nitrogen compounds in vivo. The composition, in some cases, may comprise one, two, or more uremic toxin-treating enzymes, such as urease, uricase or creatininase. The oral delivery composition may be able to deliver the uremic toxin-treating enzymes, substantially undigested, to the intestines, where the enzymes can interact with uremic toxins transported to the intestines from the bloodstream. In another aspect, the treatment includes an oral delivery composition comprising a cell able to reduce the concentration of one or more uremic toxins in vivo. In some cases, the cell may be designed to overexpress one, two, or more uremic toxin-treating enzymes, such as urease, uricase or creatininase, for example, by transfecting the cell with a corresponding gene. In some embodiments, a species able to ;react with or otherwise sequester by-products of the uremic toxin-treating enzyme reactions may be included with the oral delivery composition. For example, if the by-product is ammonium, the species may be a sorbent able to adsorb ammonium, an enzyme able to react with the ammonium, or the like.
摘要翻译：本发明一般涉及使用尿毒症毒素处理酶和/或能够产生尿毒症毒素治疗酶或以其它方式与尿毒症毒素反应的细胞体内尿毒症毒素的治疗。需要治疗尿毒症毒素的情况的非限制性实例包括肾脏疾病或功能障碍，痛风，接受化疗的受试者等。一方面，该治疗包括能够降低体内一种或多种非蛋白质氮化合物的血液浓度的口服递送组合物。在一些情况下，组合物可以包含一种，两种或更多种尿毒症毒素治疗酶，例如脲酶，尿酸酶或肌酸酐酶。口服递送组合物可以能够将基本上未消化的尿毒症毒素处理酶递送到肠道，其中酶可以与从血液输送到肠道的尿毒症毒素相互作用。在另一方面，治疗包括口服递送组合物，其包含能够降低体内一种或多种尿毒症毒素浓度的细胞。在一些情况下，细胞可被设计为过表达一种，两种或更多种尿毒症毒素治疗酶，例如脲酶，尿酸酶或肌酸酐酶，例如通过用相应的基因转染细胞。在一些实施方案中，能够与尿毒症毒素处理酶反应的副产物反应或以其它方式螯合的物质可以包含在口服递送组合物中。例如，如果副产物是铵，则该物质可以是能够吸附铵的吸附剂，能够与铵反应的酶等。

5. 发明申请

WO2015065963A1 MINERAL PRECIPITATION METHODS 审中-公开
标题翻译：矿物沉淀法
公开(公告)号：WO2015065963A1
公开(公告)日：2015-05-07
申请号：PCT/US2014/062557
申请日：2014-10-28
申请人： ARIZONA BOARD OF REGENTS, a body corporate of THE STATE OF ARIZONA, acting for and on behalf of ARIZONA STATE UNIVERSITY
发明人： KAVAZANJIAN, Edward , HAMDAN, Nasser
IPC分类号： C12N9/78 , A01G7/00
CPC分类号： E02D3/12 , C01F11/18 , C02F1/286 , C02F1/42 , C02F1/5236 , C12N9/80 , C12Y305/01005 , E02D2300/0037
摘要： The present invention provides methods for mineral precipitation of porous particulate starting materials using isolated urease.
摘要翻译：本发明提供了使用分离的脲酶对多孔微粒原料进行矿物沉淀的方法。

6. 发明申请

WO2014165985A1 USE OF ANTIBODY-UREASE CONJUGATES FOR DIAGNOSTIC AND THERAPEUTIC PURPOSES 审中-公开
标题翻译：用于诊断和治疗用途的抗体 - 尿素酶联合用途
公开(公告)号：WO2014165985A1
公开(公告)日：2014-10-16
申请号：PCT/CA2014/050334
申请日：2014-04-03
申请人： HELIX BIOPHARMA CORP.
发明人： CHAO, Heman
IPC分类号： C12N9/80 , A61K47/48 , A61P35/00 , C07K16/00 , C07K16/28 , C12N9/96
CPC分类号： C12N9/80 , A61K47/68 , A61K47/6815 , A61K47/6851 , C07K16/32 , C12N9/96 , C12Y305/01005
摘要： This disclosure provides antibody-urease conjugates having therapeutic and diagnostic utility. More specifically, the disclosure relates to diagnostic and/or therapeutic conjugates that are prepared by conjugating one or more whole antibodies to urease.
摘要翻译：本公开提供具有治疗和诊断效用的抗体 - 脲酶缀合物。更具体地，本公开涉及通过将一种或多种完整抗体与脲酶缀合制备的诊断和/或治疗性缀合物。

7. 发明申请

WO2013185215A1 ANTIBODIES AND CONJUGATES THAT TARGET MISFOLDED PRION PROTEIN 审中-公开
标题翻译：抗体和与目标蛋白质的蛋白质结合
公开(公告)号：WO2013185215A1
公开(公告)日：2013-12-19
申请号：PCT/CA2013/000569
申请日：2013-06-11
申请人： AMORFIX LIFE SCIENCES LTD. , HELIX BIOPHARMA CORP.
发明人： UGER, Marni Diane , CHAI, Viengthong , CIOLFI, Veronica , CASHMAN, Neil R. , TIAN, Baomin , WONG, Wah Yau , CHAO, Heman Lap-Man
IPC分类号： C07K16/18 , A61K39/395 , A61K47/48 , A61P35/00 , G01N33/53 , G01N33/574
CPC分类号： C07K16/2872 , A61K31/337 , A61K38/50 , A61K39/3955 , A61K47/6815 , A61K47/6843 , A61K47/6849 , C07K2317/34 , C07K2317/92 , C12Y305/01005 , G01N33/6872 , G01N33/6896 , G01N2333/70596 , G01N2800/2828
摘要： Human prion protein, PrP, selectively presents the epitope MDEYSNQNN (SEQ ID No. 14) when PrP misfolds. The misfolded form of human PrP is associated with various disease states. The present invention provides an antibody useful to detect and treat such diseases, including cancer such as ovarian cancer and lymphomas, and transmissible spongiform encephalopathies such as CJD. Also provided is an immunoconjugate in which the antibody is conjugated with urease as cytotoxin.
摘要翻译：当PrP错误折叠时，人朊蛋白PrP选择性地呈现表位MDEYSNQNN（SEQ ID No.14）。人类PrP的错误形式与各种疾病状态有关。本发明提供了可用于检测和治疗包括癌症如卵巢癌和淋巴瘤以及传染性海绵状脑病如CJD的疾病的抗体。还提供了免疫偶联物，其中抗体与脲酶作为细胞毒素缀合。

8. 发明申请

WO2005056040A3 SYSTEMS AND METHODS RELATED TO DEGRADATION OF UREMIC TOXINS 审中-公开
标题翻译：与尿毒素降解有关的系统和方法
公开(公告)号：WO2005056040A3
公开(公告)日：2005-11-03
申请号：PCT/US2004040580
申请日：2004-12-03
申请人： UNIV BROWN , O'LOUGHLIN JILL A , BRUDER JAN MARKUS , LYSAGHT MICHAEL J
发明人： O'LOUGHLIN JILL A , BRUDER JAN MARKUS , LYSAGHT MICHAEL J
IPC分类号： A61K35/66 , A61K35/74 , A61K38/43 , A61K38/44 , A61K38/50 , A61P19/06
CPC分类号： C12Y305/01005 , A61K9/4866 , A61K9/4891 , A61K38/44 , A61K38/50 , A61K38/53 , C12Y107/03003 , C12Y305/0201 , C12Y603/01002 , A61K2300/00
摘要： The present invention generally relates to the treatment of uremic toxins in vivo using uremic toxin-treating enzymes, and/or cells capable of producing uremic toxin-treating enzymes or otherwise reacting with uremic toxins. Non-limiting examples of cases where the treatment of uremic toxins is desired include renal disease or dysfunction, gout, subjects receiving chemotherapy, or the like. In one aspect, the treatment includes an oral delivery composition able to reduce the blood concentration of one or more non-protein nitrogen compounds in vivo. The composition, in some cases, may comprise one, two, or more uremic toxin-treating enzymes, such as urease, uricase or creatininase. In another aspect, the treatment includes an oral delivery composition comprising a cell able to reduce the concentration of one or more uremic toxins in vivo. In some cases, the cell may be designed to overexpress one, two, or more uremic toxin-treating enzymes, such as urease, uricase or creatininase, for example, by transfecting the cell with a corresponding gene.
摘要翻译：本发明一般涉及使用尿毒症毒素处理酶和/或能够产生尿毒症毒素治疗酶或以其它方式与尿毒症毒素反应的细胞体内尿毒症毒素的治疗。需要治疗尿毒症毒素的情况的非限制性实例包括肾脏疾病或功能障碍，痛风，接受化疗的受试者等。一方面，该治疗包括能够降低体内一种或多种非蛋白质氮化合物的血液浓度的口服递送组合物。在一些情况下，组合物可以包含一种，两种或更多种尿毒症毒素治疗酶，例如脲酶，尿酸酶或肌酸酐酶。在另一方面，治疗包括口服递送组合物，其包含能够降低体内一种或多种尿毒症毒素浓度的细胞。在一些情况下，细胞可被设计为过表达一种，两种或更多种尿毒症毒素治疗酶，例如脲酶，尿酸酶或肌酸酐酶，例如通过用相应的基因转染细胞。

9. 发明申请

WO2005052145A2 RECOMBINANT ALKALINIZING BACTERIA 审中-公开
标题翻译：重组碱性细菌
公开(公告)号：WO2005052145A2
公开(公告)日：2005-06-09
申请号：PCT/US2004/033214
申请日：2004-10-07
申请人： UNIVERSITY OF FLORIDA , BURNE, Robert, A. , YI-YWAN, Margaret, Chen
发明人： BURNE, Robert, A. , YI-YWAN, Margaret, Chen
IPC分类号： C12N9/00
CPC分类号： C12N9/80 , A61K8/0216 , A61K8/99 , A61K35/744 , A61K38/164 , A61K38/50 , A61K2800/86 , A61Q11/00 , C12Y305/01005 , C12Y305/03006 , C12Y305/03012 , A61K2300/00
摘要： Compositions and methods utilizing recombinant alkalinizing bacteria which include isolated nucleic acid constructs. The genetically engineered cells express at least one alkali producing enzyme, such as a urease, an arginine deiminase or an agmatine deiminase, which produce the alkali ammonia. When used in the mouth of a subject, the presence of alkalis raises the pH, reducing the incidence of cavities.
摘要翻译：使用重组碱化细菌的组合物和方法，其包括分离的核酸构建体。遗传工程化的细胞表达产生碱性氨的至少一种碱产生酶，例如脲酶，精氨酸脱亚胺酶或胍丁胺去酰亚胺酶。当在受试者的口中使用时，碱的存在提高了pH值，减少了腔的发生。

10. 发明申请

WO2016036658A1 DIAGNOSTIC DEVICES WITH MODIFIABLE HYDROPHOBIC SURFACES 审中-公开
标题翻译：具有可修改的疏水性表面的诊断装置
公开(公告)号：WO2016036658A1
公开(公告)日：2016-03-10
申请号：PCT/US2015/047715
申请日：2015-08-31
申请人： SIEMENS HEALTHCARE DIAGNOSTICS INC.
发明人： PERNG, John
IPC分类号： B29C65/08 , G01N30/02
CPC分类号： B01L3/5027 , B01L3/502707 , B01L3/50273 , B01L2200/0621 , B01L2300/0816 , B01L2300/0851 , B01L2300/0864 , B01L2300/0887 , B01L2300/165 , B01L2400/0406 , C12Q1/25 , C12Q1/26 , C12Q1/34 , C12Q1/40 , C12Q1/54 , C12Q1/58 , C12Y101/03004 , C12Y113/12004 , C12Y302/01108 , C12Y305/01005 , C12Y305/0201 , C12Y305/03003 , G01N27/447
摘要： A diagnostic device 10 for screening for a target analyte in a sample is provided. The diagnostic device 10 comprises a substrate 12 and a hydrophobic material 20 disposed on the substrate. The hydrophobic material 20 is selected to be converted from the hydrophobic material 20 to a hydrophilic material 22 upon contact with a conversion component within or derived from a sample introduced to the device 10.
摘要翻译：提供了用于筛选样品中的目标分析物的诊断装置10。诊断装置10包括基板12和设置在基板上的疏水材料20。当与引入到装置10的样品中的转化组分接触时，疏水材料20被选择为从疏水材料20转化为亲水材料22。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式